Literature DB >> 26382012

Single nucleotide polymorphism in the SEPS1 gene may contribute to the risk of various human diseases: a meta-analysis.

Hong-Yun Sun1, Tai-Bin Liu2, Qing-Chang Wang3, Wei-Qiang Wu3, Yu-Jing He4.   

Abstract

BACKGROUND: Recently the G-105A promoter polymorphism in SEPS1 has been shown to increase pro-inflammatory cytokine expression and, thus, to be correlated with various types of human cancers and diseases. AIMS: This study examined whether this functional polymorphism was related to the risks of several human diseases by performing a meta-analysis. SUBJECTS AND METHODS: This study identified all published studies in MEDLINE, Science Citation Index, the Cochrane Library, PubMed, Embase, Current Contents Index and three Chinese databases. RESULTS AND
CONCLUSIONS: Eleven case-control studies were incorporated into this meta-analysis. The results showed that carriers of the rs28665122 G > A polymorphism in the SEPS1 gene are at increased risk of developing diseases under five genetic models. According to the ethnicity-stratified sub-group analysis, SEPS1 rs28665122 polymorphism is significantly linked to increased risk of developing related diseases in Europeans under five genetic models; but not among Asians. This data indicates a statistical association between SEPS1 rs28665122 G > A variants and the development of various human diseases. Such findings suggest that SEPS1 may be a potential gene marker for disease diagnosis and prognosis.

Entities:  

Keywords:  Genetic polymorphism; SEPS1; human diseases; meta-analysis

Mesh:

Substances:

Year:  2015        PMID: 26382012     DOI: 10.3109/03014460.2015.1070903

Source DB:  PubMed          Journal:  Ann Hum Biol        ISSN: 0301-4460            Impact factor:   1.533


  1 in total

1.  Differential regulation of cellular stress responses by the endoplasmic reticulum-resident Selenoprotein S (Seps1) in proliferating myoblasts versus myotubes.

Authors:  Alex B Addinsall; Sheree D Martin; Fiona Collier; Xavier A Conlan; Victoria C Foletta; Nicole Stupka
Journal:  Physiol Rep       Date:  2018-12
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.